26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
11 August 2022 - Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisXENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…read more >>
04 August 2022 - F2G LtdF2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent OlorofimF2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of…read more >>
26 July 2022 - Destiny Pharma plcPublication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infectionsDestiny Pharma is currently finalising preparations for the pivotal Phase 3 clinical trial of NTCD-M3 and seeking partners to help…read more >>
19 July 2022 - GARDP FoundationGARDP in the Financial Times: Antibiotic resistance raises prospect of untreatable gonorrhoeaIt doesn’t look like there’s anything that’s going to drive new research and development of antibiotics until we reach a…read more >>
19 July 2022 - Destiny Pharma plcDestiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plansDestiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening…read more >>
18 July 2022 - Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.read more >>
17 March 2025BIO-Europe Spring® 2025 – 19th Annual International Partnering ConferenceBIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000…read more >>
25 February 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
03 December 2024REVIVE Webinar: Implementation research for the appropriate use of, and access to, antimicrobialsThis webinar will explore how implementation research has successfully led to the updating of guidelines for other drugs and discuss…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
19 September 2024REVIVE Webinar: An introduction to antibiotic research and development (R&D)Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
